The AMYPAD consortium is pleased to announce a major milestone. The Diagnostic and Patient Management Study (DPMS) has reached the 50% recruitment mark with more than 450 subjects enrolled since the study was initiated last April 2018.
The AMYPAD DPMS protocol has been approved in all seven participating countries (Switzerland, Netherlands, France, UK, Spain, Germany and Sweden). Out of a total of 900 expected participants, with an initial work-up of either subjective cognitive decline, mild cognitive impairment or suspected Alzheimer’s disease dementia, 471 research participants have already been recruited. The analysis of the PET images acquired in this study has also commenced, with the aim of determining the usefulness of ß-amyloid imaging regarding diagnostic confidence, decision trees, change in diagnosis, and patient management plans.
The AMYPAD project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115952. The Joint Undertaking receives support from the European Union’s Horizon2020 research and innovation programme and EFPIA.